These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27058302)

  • 21. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.
    Song BM; Kang HM; Lee EK; Jung SC; Kim MC; Lee YN; Kang SM; Lee YJ
    Vaccine; 2016 Jan; 34(5):678-686. PubMed ID: 26691568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope.
    Chen S; Zheng D; Li C; Zhang W; Xu W; Liu X; Fang F; Chen Z
    Biomed Res Int; 2015; 2015():901817. PubMed ID: 25767809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The large-scale production of an artificial influenza virus-like particle vaccine in silkworm pupae.
    Nerome K; Sugita S; Kuroda K; Hirose T; Matsuda S; Majima K; Kawasaki K; Shibata T; Poetri ON; Soejoedono RD; Mayasari NL; Agungpriyono S; Nerome R
    Vaccine; 2015 Jan; 33(1):117-25. PubMed ID: 25448101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances and challenges in the development and production of effective plant-based influenza vaccines.
    Yusibov V; Kushnir N; Streatfield SJ
    Expert Rev Vaccines; 2015 Apr; 14(4):519-35. PubMed ID: 25487788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
    Liu WC; Liu YY; Chen TH; Liu CC; Jan JT; Wu SC
    Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
    Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
    Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus.
    Ren Z; Ji X; Meng L; Wei Y; Wang T; Feng N; Zheng X; Wang H; Li N; Gao X; Jin H; Zhao Y; Yang S; Qin C; Gao Y; Xia X
    Virus Res; 2015 Mar; 200():9-18. PubMed ID: 25599603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
    Venereo-Sanchez A; Gilbert R; Simoneau M; Caron A; Chahal P; Chen W; Ansorge S; Li X; Henry O; Kamen A
    Vaccine; 2016 Jun; 34(29):3371-80. PubMed ID: 27155499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Process intensification for high yield production of influenza H1N1 Gag virus-like particles using an inducible HEK-293 stable cell line.
    Venereo-Sanchez A; Simoneau M; Lanthier S; Chahal P; Bourget L; Ansorge S; Gilbert R; Henry O; Kamen A
    Vaccine; 2017 Jul; 35(33):4220-4228. PubMed ID: 28648546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.
    Pushko P; Sun X; Tretyakova I; Hidajat R; Pulit-Penaloza JA; Belser JA; Maines TR; Tumpey TM
    Vaccine; 2016 Oct; 34(44):5235-5242. PubMed ID: 27663671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli.
    Lagoutte P; Mignon C; Donnat S; Stadthagen G; Mast J; Sodoyer R; Lugari A; Werle B
    J Virol Methods; 2016 Jun; 232():8-11. PubMed ID: 26947397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection induced by early stage vaccination with pandemic influenza virus-like particles.
    Lee GJ; Quan FS
    Vaccine; 2016 Jul; 34(33):3764-72. PubMed ID: 27317263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Immunogenicity of a Potyvirus-Like Particle as an Adjuvant of a Synthetic Peptide.
    Cárdenas-Vargas A; Elizondo-Quiroga D; Gutierrez-Ortega A; Charles-Niño C; Pedroza-Roldán C
    Viral Immunol; 2016 Dec; 29(10):557-564. PubMed ID: 27834623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.